From professional translators, enterprises, web pages and freely available translation repositories.
hyperparatyroidisme
hyperparathyroidism
Last Update: 2017-04-26
Usage Frequency: 7
Quality:
sekundær hyperparatyroidisme
secondary hyperparathyroidism
Last Update: 2017-04-26
Usage Frequency: 2
Quality:
ikke kendt: sekundær hyperparatyroidisme.
not known: hyperparathyroidism secondary.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
ved hyperparatyroidisme producerer biskjoldbruskkirtlerne for meget
this is a condition where the parathyroid glands produce too much
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
ikke kendt: sekundær hyperparatyroidisme, thyroidit.
not known: hyperparathyroidism secondary, thyroiditis.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
hvis de er under behandling for sekundær hyperparatyroidisme
if you are being treated for secondary hyperparathyroidism
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
markant hypercalcæmi kan være tegn på skjult hyperparatyroidisme.
marked hypercalcaemia may be evidence of hidden hyperparathyroidism.
Last Update: 2012-04-12
Usage Frequency: 2
Quality:
tydelig hyperkalcæmi kan være et tegn på skjult hyperparatyroidisme.
marked hypercalcaemia may be evidence of hidden hyperparathyroidism.
Last Update: 2008-03-04
Usage Frequency: 9
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
ved primær og sekundær hyperparatyroidisme afgiver biskjoldbruskkirtlerne for meget pth.
in primary and secondary hyperparathyroidism too much pth is produced by the parathyroid glands.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
ved hyperparatyroidisme, der skyldes nyresygdom, er den anbefalede startdosis til voksne 30 mg én gang dagligt.
in hyperparathyroidism caused by kidney disease, the recommended starting dose for adults is 30 mg once a day.
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
denne risiko er øget ved samtidig anvendelse af fluorquinoloner og hos dialysepatienter med sekundær hyperparatyroidisme samt efter nyretransplantation.
this risk is increased by concomitant use of fluoroquinolones and in patients undergoing dialysis with secondary hyperparathyroidism or after renal transplantation.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
at behandle sekundær hyperparatyroidisme hos patienter med alvorlig nyresygdom, der kræver dialyse for at rense blodet for affaldsstoffer.
treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
mimpara blev desuden anvendt i en undersøgelse med 21 patienter med kræft i biskjoldbruskkirtlerne og 8 patienter med hyperparatyroidisme af anden årsag end nyresygdom.
mimpara has also been studied in 21 patients with parathyroid carcinoma and 8 patients with hyperparathyroidism not caused by kidney disease.
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
behandling af sekundær hyperparatyroidisme (hpt) hos patienter med slutstadium af nyresygdom (esrd) i vedligeholdelsesdialyseterapi.
treatment of secondary hyperparathyroidism (hpt) in patients with end-stage renal disease (esrd) on maintenance dialysis therapy.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
behandling af sekundær hyperparatyroidisme (hpt) hos patienter med slutstadium af nyresygdom (esrd) i vedligeholdelsesdia lyseterapi.
treatment of secondary hyperparathyroidism (hpt) in patients with end-stage renal disease (esrd) on maintenance dialysis therapy.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
mimpara fik kalciumindholdet i blodet til at falde med mere end 1 mg pr. dl hos 15 ud af 21 af kræftpatienterne og hos 6 ud af 8 patienter med hyperparatyroidisme af anden årsag end nyresygdom.
mimpara produced a decrease in blood calcium of more than 1 mg per dl in 15 out of 21 cancer patients and in 6 out of 8 patients with hyperparathyroidism not caused by kidney disease.
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
udvalget for humanmedicinske lægemidler (chmp) konkluderede, at mimpara er påvist at være effektivt til behandling af hyperparatyroidisme hos dialysepatienter med nyresygdom i sent stadium.
the committee for medicinal products for human use (chmp) concluded that mimpara effectiveness in the treatment hyperparathyroidism in dialysis patients with end stage renal disease had been shown.
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
selvom hyperparatyroidisme ikke blev rapporteret i ca209017, kan immunrelateret hyperparatyroidisme overvejes, især hvis det er associeret med hypofosfatæmi (rapporteret hos 6 patienter med hyperkalcæmi i dette studie).
although hyperparathyroidism was not reported in ca209017, immune-related hyperparathyroidism might be considered especially if associated with hypophosphataemia (reported in 6 hypercalcemic patients in this study).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
i nogle prækliniske toksikologiske undersøgelser med hunde og rotter, men ikke aber, blev erytropoietin-terapien associeret med subklinisk knoglemarvsfibrose (knoglemarvsfibrose er en kendt komplikation ved kronisk nyresvigt hos mennesker og kan relateres til sekundær hyperparatyroidisme
in some pre-clinical toxicological studies in dogs and rats, but not in monkeys, erythropoietin therapy was associated with subclinical bone marrow fibrosis (bone marrow fibrosis is a known complication of chronic renal failure in humans and may be related to secondary hyperparathyroidism or unknown factors.
Last Update: 2008-03-04
Usage Frequency: 22
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
i nogle prækliniske toksikologiske undersøgelser med hunde og rotter, men ikke aber, blev erytropoietin- terapien associeret med subklinisk knoglemarvsfibrose (knoglemarvsfibrose er en kendt komplikation ved kronisk nyresvigt hos mennesker og kan relateres til sekundær hyperparatyroidisme eller ukendte faktorer.
in some pre-clinical toxicological studies in dogs and rats, but not in monkeys, erythropoietin therapy was associated with subclinical bone marrow fibrosis (bone marrow fibrosis is a known complication of chronic renal failure in humans and may be related to secondary hyperparathyroidism or unknown factors.
Last Update: 2012-04-12
Usage Frequency: 2
Quality: